Management & Regulatory

Will Alyftrek Revolutionize CF Treatment in Europe?
Management & Regulatory Will Alyftrek Revolutionize CF Treatment in Europe?

In the realm of cystic fibrosis treatment, the recent European Commission approval of Vertex Pharmaceuticals' Alyftrek represents a significant leap forward. Ivan Kairatov, a biopharma expert deeply versed in technological and innovative advancements, provides his insights on this novel therapy and

Is Ziihera a Game-Changer for HER2-Positive Biliary Cancer?
Management & Regulatory Is Ziihera a Game-Changer for HER2-Positive Biliary Cancer?

Introducing Ivan Kairatov, a biopharma expert renowned for his insights into pharmaceutical technology and innovation, particularly in research and development. Today, we're delving into a groundbreaking moment for biliary tract cancer treatment with the conditional approval of Jazz

Can Lynozyfic Transform Multiple Myeloma Treatment?
Management & Regulatory Can Lynozyfic Transform Multiple Myeloma Treatment?

Ivan Kairatov is an esteemed biopharma expert with extensive knowledge in technological innovation within the industry, particularly in research and development. Today, we'll delve into the recent FDA approval of Regeneron's Lynozyfic for multiple myeloma and its implications for patients and

Are Patient-Friendly Drug Formulations the Future of Cancer Care?
Management & Regulatory Are Patient-Friendly Drug Formulations the Future of Cancer Care?

The field of cancer treatment has witnessed significant innovations, especially in the formulation of drugs designed to ease patient administration. The European Medicines Agency's endorsement of zanubrutinib tablets, Brukinsa's newer form, highlights an essential shift toward treatments that

FDA Approves Gamifant for Treating Macrophage Activation Syndrome
Management & Regulatory FDA Approves Gamifant for Treating Macrophage Activation Syndrome

In the world of biopharmaceutical innovations, Ivan Kairatov stands out as an expert in tech and development. His insights into the recent FDA approval of Gamifant are invaluable, particularly regarding its role in treating macrophage activation syndrome (MAS) associated with Still's disease. This

New Zealand's Urgent Need for Enhanced Dementia Psychiatric Care
Management & Regulatory New Zealand's Urgent Need for Enhanced Dementia Psychiatric Care

New Zealand faces an urgent challenge in addressing the mental health needs of older adults with dementia, particularly those exhibiting psychiatric symptoms. Despite comprehensive recognition of the nation's mental health crisis through inquiries like He Ara Oranga, a glaring gap persists in

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later